-
-
-
-
-
-
-
Truist Securities Reiterates Buy Rating on AbCellera Biologics (ABCL)
-
-
-
-
-
-
-
AbCellera (ABCL) Misses Q3 EPS by 5c
-
-
-
-
-
-
-
AbCellera's (ABCL) Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit
-
-
-
-
-
-
-
AbCellera (ABCL) Tops Q3 EPS by 1c
-
-
-
-
-
-
413,003 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

